Minerva Neurosciences, Inc. (NASDAQ:NERV) Files An 8-K Regulation FD Disclosure


Minerva Neurosciences, Inc. (NASDAQ:NERV) Files An 8-K Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure

On December 5, 2016, Minerva Neurosciences, Inc. (the Company)
issued a press release announcing its presentations of data from
the Companys Phase IIA and Phase IIB trials with MIN-101 and
Phase IIA trial with MIN-117 at the 55th Annual Meeting of the American
College of Neuropsychopharmacology.

A copy of the above referenced press release is furnished as
Exhibit 99.1 to this Current Report on Form 8-K. This
information, including the information contained in the press
release furnished as Exhibit 99.1, shall not be deemed filed for
purposes of Section18 of the Securities Exchange Act of 1934, as
amended, and is not incorporated by reference into any of the
Companys filings, whether made before or after the date hereof,
regardless of any general incorporation language in any such

Item 9.01. Financial Statements and

(d) Exhibits



99.1 Press Release of the Company dated December 5, 2016

About Minerva Neurosciences, Inc. (NASDAQ:NERV)

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio include MIN-101 for the treatment of schizophrenia; MIN-117 for the treatment of major depressive disorder (MDD); MIN-202 (also known as JNJ-42847922) for the treatment of insomnia disorder and adjunctive MDD, and MIN-301 for the treatment of Parkinson’s disease. MIN-101 blocks serotonin receptors and sigma receptors, over two receptors in the brain that are involved in the regulation of mood, cognition, sleep and anxiety. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-HT1A. MIN-202 is a selective orexin 2 receptor antagonist it is developing in collaboration with Janssen Pharmaceutica NV. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 protein.

Minerva Neurosciences, Inc. (NASDAQ:NERV) Recent Trading Information

Minerva Neurosciences, Inc. (NASDAQ:NERV) closed its last trading session up +0.55 at 13.10 with 104,824 shares trading hands.